Company intelligence / Profile preview

PACT Pharma

South San Francisco, California, United Statespactpharma.com ↗
Ownership
Private
Employees
~50
Development stage
Other
01

Overview

The company was developing T-cell therapies for solid tumors with its lead candidate NeoTCR-P1 in Phase 1 clinical trials before restructuring and layoffs in 2022

Therapeutic areas
Oncology
Modalities
T-cell therapiesTCR-T Cell therapy
Industry
Biotech
02

Drug pipeline

3 assets

NeoTCR-P1

1

2 more assets in the full pipeline.

03

Partnerships

Lyell Immunopharma

Beyond the preview

Go deeper on PACT Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PACT Pharma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call